← Radiopharm Theranostics Ltd (RADX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Radiopharm Theranostics Ltd (RADX)
Pharmaceutical Preparations · market cap $23M · as of 2026-07-11
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
2
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Radiopharm Theranostics Ltd (RADX) is a radiopharmaceutical-focused biotech with 14 employees and a market cap of approximately $10.5B at ~$4.37/share. Its lead asset, 177Lu-BetaBart, is in Phase 2 for castration-resistant prostate cancer (CRPC), alongside RAD101 (18F-FPIA), a Phase 2 PET diagnostic agent for brain metastases from solid tumors. The company has disclosed no recent or upcoming catalysts, and key financial metrics including cash, runway, and dilution are not available.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| 177Lu-BetaBart | Phase 2 | Castration-Resistant Prostate Cancer (CRPC) |
| RAD101 (18F-FPIA) | Phase 2 | Brain Metastases From Solid Tumors |
Price & technical context
3-month
-61.9%
6-month
-62.3%
12-month
-72.1%
52-wk range
$1.52–$10.63
vs 50-day MA
-33.4%
vs 200-day MA
-61.0%
Realized vol
129.1%
Max drawdown
-92.0%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for RADX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.